Hepatitis B Virus Surface Antigen, Confirmation
Also known as: HBSAG CONF
Use
This test is used to confirm the presence of Hepatitis B surface antigen (HBsAg) in a patient's serum or plasma, indicating an acute or chronic hepatitis B infection. It is crucial for clinical diagnosis and management of hepatitis B infection, as it confirms ongoing infection and assists in determining the appropriate therapeutic and preventive measures. This assay is not intended for blood donor screening or screening for human cells, tissues, and cellular- and tissue-based products (HCT/P).
Special Instructions
Not provided.
Limitations
The test is not suitable for blood donor screening, associated reentry protocols, or for screening human cells, tissues, and cellular- and tissue-based products (HCT/P). False positive and negative results can occur; therefore, results should be interpreted in the context of clinical evidence and repeat testing might be necessary to clarify diagnosis if a result is not supported clinically.
FDA ApprovedNew York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
Hepatitis B Surface Antigen
Protein
LOINC Codes
- 65633-0 - HBV surface Ag SerPl Ql Cfm
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2.5 mL
Minimum Volume
1.5 mL
Container
ARUP standard transport tube
Collection Instructions
Collect in a serum separator tube. Also acceptable: Lavender (EDTA) or pink (K2EDTA). Separate serum or plasma from cells ASAP or within 2 hours of collection.
Storage Instructions
Refrigerated storage and transport. Avoid repeated freeze/thaw cycles.
Causes for Rejection
Heparinized plasma, specimens containing particulate material, heat-inactivated, severely hemolyzed, or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 1 week |
| Frozen | Indefinitely |
Other tests from different labs that may be relevant